VYNE Therapeutics Inc.
VYNE
$0.59
$0.000.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 33.52% | 0.98% | -35.59% | -45.11% | -40.00% |
| Total Depreciation and Amortization | 475.00% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 78.11% | 7.24% | -36.66% | -54.58% | -71.85% |
| Change in Net Operating Assets | -263.91% | -318.32% | -1,884.17% | 412.17% | 8,231.67% |
| Cash from Operations | 2.50% | -27.40% | -48.67% | -34.51% | -34.06% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 59.13% | 180.74% | 169.37% | 171.12% | 140.94% |
| Cash from Investing | 59.93% | 180.51% | 169.12% | 170.94% | 140.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -1.42% | -2,263.64% | -355.36% | -277.97% | -110.45% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1.42% | -100.31% | -100.31% | -100.27% | -100.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 138.16% | 270.50% | -184.97% | 181.44% | -3,470.76% |